Todd Walker is the Executive Director and Chief Strategist at HedgeTracker, where he is responsible for overseeing research, analytics and business development. He has particular expertise in investments that are popular among elite hedge fund managers, shareholder activists and green/sustainability-oriented investors. Prior to joining HedgeTracker in 2003, Mr. Walker headed up a hedge fund research team at a Fortune 1000 financial firm.
Fxpips.com is your one-stop website when it comes to the latest buzz happening around the foreign exchange market. Manned by financial experts and veterans in foreign exchange, fxpips.com is your total online destination for current news that shapes the financial trading landscape.
Jay Singh is a finance enthusiast. Reading and blogging about finance in general and hedge funds in particular is both a passion and a professional way to find opportunities.
Currently, Jay mainly advises on global private equity but previously managed publicly-traded instruments both for institutions and family offices for over a decade. Hand in hand with global finance, he is also an active participant in technology start ups.
Small-Cap PM and Analyst. I love to be first at bat, hitting the micro/small cap stock home-runs. I'm a portfolio builder and stock picker w/o the fluff, one who likes to avoid the crowds and the stock of the day. I'm not a stock collector (market dynamics have changed, love affairs with stocks are so yesterday)--today, a buy and hold strategy must come with an expiration date. I'm forever a thematic player; I carve out positions with an eye on tomorrow's horizon--what technology or medical break-through is going to define a sector over time. The merits of my investment selection is proven worthy only if other investors (horses) eventually follow my lead and find my watering hole.
At Investment Underground, our editors are disciplined, independent journalists who dig into technology, commodities, and stock market news to break the stories that matter. Our active approach to journalism spans analysis and interviews with noteworthy leaders to uncover real news that affects business right now.
Most notably, our insights predicted the departure of Avon CEO, Andrea Jung, and Warren Buffett’s purchase of his first technology stock in over forty years at Berkshire Hathaway.
Our work appears in Google News, Seeking Alpha, Motley Fool, Morningstar, Vatalyst, Value Walk, and Guru Focus, among others.
Edward Graham is Senior Analyst/Consultant, previously responsible for all healthcare positions in the UBS U.S. Small Cap Funds. He has 13 years of buy-side experience in Healthcare with a specialty in Medical Devices and Biotech investing. While at UBS, he developed a unique biotech investment strategy that captured alpha and reduced event risk. The strategy involved buying a basket of small cap biotech stocks with strong cash positions, diverse pipelines, and solid management teams.
Edward is dedicated to growth investing with expertise as a partner for an independent asset management boutique and as an investment team member for a multinational financial institution. Unique accomplishments include driving the growth of a start-up investment firm from $250M to $2B in AUM.
Ijeoma Charles Onuosa is a US-based commercial financier and venture capitalist whose holding company has interests in consumer products, mortgage, insurance, and construction-related businesses all partially financed by a wholly-owned proprietary trading unit. Onuosa's group is narrowly focused on nano-cap companies with businesses operating in the industrial and consumer goods sectors internationally.
Marc is a frequent contributor to Investment U and also The Oxford Club’s Income Specialist and Editor of The Oxford Income Letter. He is the author of the best seller "Get Rich with Dividends".
His investment career started out at the trading desk of Carlin Equities in San Francisco, CA, where he executed dozens of trades each day for his clients.
As a Senior Analyst with Avalon Research Group, his buy recommendation gained 17.8% versus the S&P 500′s 5.9%. While there, Marc started and headed the technical research products division, in addition to his fundamental duties.
Marc also looked at the market with a journalist’s skeptical eye as a columnist for The Street, where he broke several stories on companies in the biotech sector. His contrarian recommendations (including shorts) gained 12.6% annualized versus the S&P 500′s gain of 0.5%.
Along with Oxford Club publications, Marc has appeared on Fox Business, Bloomberg Radio, Yahoo! Finance and been published in the online version of The Wall Street Journal, The Street, U.S News and World Report and was featured on NPR’s “The Story.”
Disclaimer: Money Morning and Stansberry & Associates Investment Research are separate companies, and entirely distinct. Their only common thread is a shared parent company, Agora Inc. Agora Inc. was named in the suit by the SEC and was exonerated by the court, and thus dropped from the case. Stansberry & Associates was found civilly liable for a matter that dealt with one writer’s report on a company. The action was not a criminal matter. The case is still on appeal, and no final decision has been made.